Global Insulin Biosimilars Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
Page: 111
Published Date: 02 Jan 2024
Category: Pharma & Healthcare
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
According to our (Global Info Research) latest study, the global Insulin Biosimilars market size was valued at USD 1522.8 million in 2023 and is forecast to a readjusted size of USD 1917.9 million by 2030 with a CAGR of 3.3% during review period.
Biosimilar insulin is likely to enter the insulin landscape as patents for major branded insulin products start to expire in the next few years. Biosimilar insulin has the potential to reduce diabetes treatment costs, increase the accessibility of insulin treatment, and expand the number of insulin brands available for those with diabetes.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Insulin Biosimilars industry chain, the market status of Type I Diabetes (Rapid-Acting Biosimilars, Long-Acting Biosimilars), Type II Diabetes (Rapid-Acting Biosimilars, Long-Acting Biosimilars), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Insulin Biosimilars.
Regionally, the report analyzes the Insulin Biosimilars markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Insulin Biosimilars market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Insulin Biosimilars market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Insulin Biosimilars industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Rapid-Acting Biosimilars, Long-Acting Biosimilars).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Insulin Biosimilars market.
Regional Analysis: The report involves examining the Insulin Biosimilars market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Insulin Biosimilars market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Insulin Biosimilars:
Company Analysis: Report covers individual Insulin Biosimilars manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Insulin Biosimilars This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Type I Diabetes, Type II Diabetes).
Technology Analysis: Report covers specific technologies relevant to Insulin Biosimilars. It assesses the current state, advancements, and potential future developments in Insulin Biosimilars areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Insulin Biosimilars market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Insulin Biosimilars market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Rapid-Acting Biosimilars
Long-Acting Biosimilars
Premixed Biosimilars
Market segment by Application
Type I Diabetes
Type II Diabetes
Major players covered
Sanofi S.A.
Boehringer Ingelheim
Eli Lilly & Co.
Novo Nordisk A/S
Biocon
Geropharm
Wockhardt
Gan&Lee Pharmaceuticals
The United Laboratories International
Tonghua Dongbao Pharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Insulin Biosimilars product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Insulin Biosimilars, with price, sales, revenue and global market share of Insulin Biosimilars from 2019 to 2024.
Chapter 3, the Insulin Biosimilars competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Insulin Biosimilars breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Insulin Biosimilars market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Insulin Biosimilars.
Chapter 14 and 15, to describe Insulin Biosimilars sales channel, distributors, customers, research findings and conclusion.
Table of Contents
1 Market Overview
1.1 Product Overview and Scope of Insulin Biosimilars
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Insulin Biosimilars Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Rapid-Acting Biosimilars
1.3.3 Long-Acting Biosimilars
1.3.4 Premixed Biosimilars
1.4 Market Analysis by Application
1.4.1 Overview: Global Insulin Biosimilars Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Type I Diabetes
1.4.3 Type II Diabetes
1.5 Global Insulin Biosimilars Market Size & Forecast
1.5.1 Global Insulin Biosimilars Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Insulin Biosimilars Sales Quantity (2019-2030)
1.5.3 Global Insulin Biosimilars Average Price (2019-2030)
2.1 Sanofi S.A.
2.1.1 Sanofi S.A. Details
2.1.2 Sanofi S.A. Major Business
2.1.3 Sanofi S.A. Insulin Biosimilars Product and Services
2.1.4 Sanofi S.A. Insulin Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Sanofi S.A. Recent Developments/Updates
2.2 Boehringer Ingelheim
2.2.1 Boehringer Ingelheim Details
2.2.2 Boehringer Ingelheim Major Business
2.2.3 Boehringer Ingelheim Insulin Biosimilars Product and Services
2.2.4 Boehringer Ingelheim Insulin Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Boehringer Ingelheim Recent Developments/Updates
2.3 Eli Lilly & Co.
2.3.1 Eli Lilly & Co. Details
2.3.2 Eli Lilly & Co. Major Business
2.3.3 Eli Lilly & Co. Insulin Biosimilars Product and Services
2.3.4 Eli Lilly & Co. Insulin Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Eli Lilly & Co. Recent Developments/Updates
2.4 Novo Nordisk A/S
2.4.1 Novo Nordisk A/S Details
2.4.2 Novo Nordisk A/S Major Business
2.4.3 Novo Nordisk A/S Insulin Biosimilars Product and Services
2.4.4 Novo Nordisk A/S Insulin Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Novo Nordisk A/S Recent Developments/Updates
2.5 Biocon
2.5.1 Biocon Details
2.5.2 Biocon Major Business
2.5.3 Biocon Insulin Biosimilars Product and Services
2.5.4 Biocon Insulin Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Biocon Recent Developments/Updates
2.6 Geropharm
2.6.1 Geropharm Details
2.6.2 Geropharm Major Business
2.6.3 Geropharm Insulin Biosimilars Product and Services
2.6.4 Geropharm Insulin Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Geropharm Recent Developments/Updates
2.7 Wockhardt
2.7.1 Wockhardt Details
2.7.2 Wockhardt Major Business
2.7.3 Wockhardt Insulin Biosimilars Product and Services
2.7.4 Wockhardt Insulin Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Wockhardt Recent Developments/Updates
2.8 Gan&Lee Pharmaceuticals
2.8.1 Gan&Lee Pharmaceuticals Details
2.8.2 Gan&Lee Pharmaceuticals Major Business
2.8.3 Gan&Lee Pharmaceuticals Insulin Biosimilars Product and Services
2.8.4 Gan&Lee Pharmaceuticals Insulin Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Gan&Lee Pharmaceuticals Recent Developments/Updates
2.9 The United Laboratories International
2.9.1 The United Laboratories International Details
2.9.2 The United Laboratories International Major Business
2.9.3 The United Laboratories International Insulin Biosimilars Product and Services
2.9.4 The United Laboratories International Insulin Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 The United Laboratories International Recent Developments/Updates
2.10 Tonghua Dongbao Pharmaceutical
2.10.1 Tonghua Dongbao Pharmaceutical Details
2.10.2 Tonghua Dongbao Pharmaceutical Major Business
2.10.3 Tonghua Dongbao Pharmaceutical Insulin Biosimilars Product and Services
2.10.4 Tonghua Dongbao Pharmaceutical Insulin Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Tonghua Dongbao Pharmaceutical Recent Developments/Updates
3.1 Global Insulin Biosimilars Sales Quantity by Manufacturer (2019-2024)
3.2 Global Insulin Biosimilars Revenue by Manufacturer (2019-2024)
3.3 Global Insulin Biosimilars Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Insulin Biosimilars by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Insulin Biosimilars Manufacturer Market Share in 2023
3.4.2 Top 6 Insulin Biosimilars Manufacturer Market Share in 2023
3.5 Insulin Biosimilars Market: Overall Company Footprint Analysis
3.5.1 Insulin Biosimilars Market: Region Footprint
3.5.2 Insulin Biosimilars Market: Company Product Type Footprint
3.5.3 Insulin Biosimilars Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4.1 Global Insulin Biosimilars Market Size by Region
4.1.1 Global Insulin Biosimilars Sales Quantity by Region (2019-2030)
4.1.2 Global Insulin Biosimilars Consumption Value by Region (2019-2030)
4.1.3 Global Insulin Biosimilars Average Price by Region (2019-2030)
4.2 North America Insulin Biosimilars Consumption Value (2019-2030)
4.3 Europe Insulin Biosimilars Consumption Value (2019-2030)
4.4 Asia-Pacific Insulin Biosimilars Consumption Value (2019-2030)
4.5 South America Insulin Biosimilars Consumption Value (2019-2030)
4.6 Middle East and Africa Insulin Biosimilars Consumption Value (2019-2030)
5.1 Global Insulin Biosimilars Sales Quantity by Type (2019-2030)
5.2 Global Insulin Biosimilars Consumption Value by Type (2019-2030)
5.3 Global Insulin Biosimilars Average Price by Type (2019-2030)
6.1 Global Insulin Biosimilars Sales Quantity by Application (2019-2030)
6.2 Global Insulin Biosimilars Consumption Value by Application (2019-2030)
6.3 Global Insulin Biosimilars Average Price by Application (2019-2030)
7.1 North America Insulin Biosimilars Sales Quantity by Type (2019-2030)
7.2 North America Insulin Biosimilars Sales Quantity by Application (2019-2030)
7.3 North America Insulin Biosimilars Market Size by Country
7.3.1 North America Insulin Biosimilars Sales Quantity by Country (2019-2030)
7.3.2 North America Insulin Biosimilars Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8.1 Europe Insulin Biosimilars Sales Quantity by Type (2019-2030)
8.2 Europe Insulin Biosimilars Sales Quantity by Application (2019-2030)
8.3 Europe Insulin Biosimilars Market Size by Country
8.3.1 Europe Insulin Biosimilars Sales Quantity by Country (2019-2030)
8.3.2 Europe Insulin Biosimilars Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9.1 Asia-Pacific Insulin Biosimilars Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Insulin Biosimilars Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Insulin Biosimilars Market Size by Region
9.3.1 Asia-Pacific Insulin Biosimilars Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Insulin Biosimilars Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10.1 South America Insulin Biosimilars Sales Quantity by Type (2019-2030)
10.2 South America Insulin Biosimilars Sales Quantity by Application (2019-2030)
10.3 South America Insulin Biosimilars Market Size by Country
10.3.1 South America Insulin Biosimilars Sales Quantity by Country (2019-2030)
10.3.2 South America Insulin Biosimilars Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11.1 Middle East & Africa Insulin Biosimilars Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Insulin Biosimilars Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Insulin Biosimilars Market Size by Country
11.3.1 Middle East & Africa Insulin Biosimilars Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Insulin Biosimilars Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12.1 Insulin Biosimilars Market Drivers
12.2 Insulin Biosimilars Market Restraints
12.3 Insulin Biosimilars Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13.1 Raw Material of Insulin Biosimilars and Key Manufacturers
13.2 Manufacturing Costs Percentage of Insulin Biosimilars
13.3 Insulin Biosimilars Production Process
13.4 Insulin Biosimilars Industrial Chain
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Insulin Biosimilars Typical Distributors
14.3 Insulin Biosimilars Typical Customers
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Table of Figures
List of Tables
Table 1. Global Insulin Biosimilars Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Insulin Biosimilars Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Sanofi S.A. Basic Information, Manufacturing Base and Competitors
Table 4. Sanofi S.A. Major Business
Table 5. Sanofi S.A. Insulin Biosimilars Product and Services
Table 6. Sanofi S.A. Insulin Biosimilars Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Sanofi S.A. Recent Developments/Updates
Table 8. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 9. Boehringer Ingelheim Major Business
Table 10. Boehringer Ingelheim Insulin Biosimilars Product and Services
Table 11. Boehringer Ingelheim Insulin Biosimilars Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. Boehringer Ingelheim Recent Developments/Updates
Table 13. Eli Lilly & Co. Basic Information, Manufacturing Base and Competitors
Table 14. Eli Lilly & Co. Major Business
Table 15. Eli Lilly & Co. Insulin Biosimilars Product and Services
Table 16. Eli Lilly & Co. Insulin Biosimilars Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Eli Lilly & Co. Recent Developments/Updates
Table 18. Novo Nordisk A/S Basic Information, Manufacturing Base and Competitors
Table 19. Novo Nordisk A/S Major Business
Table 20. Novo Nordisk A/S Insulin Biosimilars Product and Services
Table 21. Novo Nordisk A/S Insulin Biosimilars Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. Novo Nordisk A/S Recent Developments/Updates
Table 23. Biocon Basic Information, Manufacturing Base and Competitors
Table 24. Biocon Major Business
Table 25. Biocon Insulin Biosimilars Product and Services
Table 26. Biocon Insulin Biosimilars Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. Biocon Recent Developments/Updates
Table 28. Geropharm Basic Information, Manufacturing Base and Competitors
Table 29. Geropharm Major Business
Table 30. Geropharm Insulin Biosimilars Product and Services
Table 31. Geropharm Insulin Biosimilars Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 32. Geropharm Recent Developments/Updates
Table 33. Wockhardt Basic Information, Manufacturing Base and Competitors
Table 34. Wockhardt Major Business
Table 35. Wockhardt Insulin Biosimilars Product and Services
Table 36. Wockhardt Insulin Biosimilars Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 37. Wockhardt Recent Developments/Updates
Table 38. Gan&Lee Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 39. Gan&Lee Pharmaceuticals Major Business
Table 40. Gan&Lee Pharmaceuticals Insulin Biosimilars Product and Services
Table 41. Gan&Lee Pharmaceuticals Insulin Biosimilars Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 42. Gan&Lee Pharmaceuticals Recent Developments/Updates
Table 43. The United Laboratories International Basic Information, Manufacturing Base and Competitors
Table 44. The United Laboratories International Major Business
Table 45. The United Laboratories International Insulin Biosimilars Product and Services
Table 46. The United Laboratories International Insulin Biosimilars Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 47. The United Laboratories International Recent Developments/Updates
Table 48. Tonghua Dongbao Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 49. Tonghua Dongbao Pharmaceutical Major Business
Table 50. Tonghua Dongbao Pharmaceutical Insulin Biosimilars Product and Services
Table 51. Tonghua Dongbao Pharmaceutical Insulin Biosimilars Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 52. Tonghua Dongbao Pharmaceutical Recent Developments/Updates
Table 53. Global Insulin Biosimilars Sales Quantity by Manufacturer (2019-2024) & (K Units)
Table 54. Global Insulin Biosimilars Revenue by Manufacturer (2019-2024) & (USD Million)
Table 55. Global Insulin Biosimilars Average Price by Manufacturer (2019-2024) & (USD/Unit)
Table 56. Market Position of Manufacturers in Insulin Biosimilars, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
Table 57. Head Office and Insulin Biosimilars Production Site of Key Manufacturer
Table 58. Insulin Biosimilars Market: Company Product Type Footprint
Table 59. Insulin Biosimilars Market: Company Product Application Footprint
Table 60. Insulin Biosimilars New Market Entrants and Barriers to Market Entry
Table 61. Insulin Biosimilars Mergers, Acquisition, Agreements, and Collaborations
Table 62. Global Insulin Biosimilars Sales Quantity by Region (2019-2024) & (K Units)
Table 63. Global Insulin Biosimilars Sales Quantity by Region (2025-2030) & (K Units)
Table 64. Global Insulin Biosimilars Consumption Value by Region (2019-2024) & (USD Million)
Table 65. Global Insulin Biosimilars Consumption Value by Region (2025-2030) & (USD Million)
Table 66. Global Insulin Biosimilars Average Price by Region (2019-2024) & (USD/Unit)
Table 67. Global Insulin Biosimilars Average Price by Region (2025-2030) & (USD/Unit)
Table 68. Global Insulin Biosimilars Sales Quantity by Type (2019-2024) & (K Units)
Table 69. Global Insulin Biosimilars Sales Quantity by Type (2025-2030) & (K Units)
Table 70. Global Insulin Biosimilars Consumption Value by Type (2019-2024) & (USD Million)
Table 71. Global Insulin Biosimilars Consumption Value by Type (2025-2030) & (USD Million)
Table 72. Global Insulin Biosimilars Average Price by Type (2019-2024) & (USD/Unit)
Table 73. Global Insulin Biosimilars Average Price by Type (2025-2030) & (USD/Unit)
Table 74. Global Insulin Biosimilars Sales Quantity by Application (2019-2024) & (K Units)
Table 75. Global Insulin Biosimilars Sales Quantity by Application (2025-2030) & (K Units)
Table 76. Global Insulin Biosimilars Consumption Value by Application (2019-2024) & (USD Million)
Table 77. Global Insulin Biosimilars Consumption Value by Application (2025-2030) & (USD Million)
Table 78. Global Insulin Biosimilars Average Price by Application (2019-2024) & (USD/Unit)
Table 79. Global Insulin Biosimilars Average Price by Application (2025-2030) & (USD/Unit)
Table 80. North America Insulin Biosimilars Sales Quantity by Type (2019-2024) & (K Units)
Table 81. North America Insulin Biosimilars Sales Quantity by Type (2025-2030) & (K Units)
Table 82. North America Insulin Biosimilars Sales Quantity by Application (2019-2024) & (K Units)
Table 83. North America Insulin Biosimilars Sales Quantity by Application (2025-2030) & (K Units)
Table 84. North America Insulin Biosimilars Sales Quantity by Country (2019-2024) & (K Units)
Table 85. North America Insulin Biosimilars Sales Quantity by Country (2025-2030) & (K Units)
Table 86. North America Insulin Biosimilars Consumption Value by Country (2019-2024) & (USD Million)
Table 87. North America Insulin Biosimilars Consumption Value by Country (2025-2030) & (USD Million)
Table 88. Europe Insulin Biosimilars Sales Quantity by Type (2019-2024) & (K Units)
Table 89. Europe Insulin Biosimilars Sales Quantity by Type (2025-2030) & (K Units)
Table 90. Europe Insulin Biosimilars Sales Quantity by Application (2019-2024) & (K Units)
Table 91. Europe Insulin Biosimilars Sales Quantity by Application (2025-2030) & (K Units)
Table 92. Europe Insulin Biosimilars Sales Quantity by Country (2019-2024) & (K Units)
Table 93. Europe Insulin Biosimilars Sales Quantity by Country (2025-2030) & (K Units)
Table 94. Europe Insulin Biosimilars Consumption Value by Country (2019-2024) & (USD Million)
Table 95. Europe Insulin Biosimilars Consumption Value by Country (2025-2030) & (USD Million)
Table 96. Asia-Pacific Insulin Biosimilars Sales Quantity by Type (2019-2024) & (K Units)
Table 97. Asia-Pacific Insulin Biosimilars Sales Quantity by Type (2025-2030) & (K Units)
Table 98. Asia-Pacific Insulin Biosimilars Sales Quantity by Application (2019-2024) & (K Units)
Table 99. Asia-Pacific Insulin Biosimilars Sales Quantity by Application (2025-2030) & (K Units)
Table 100. Asia-Pacific Insulin Biosimilars Sales Quantity by Region (2019-2024) & (K Units)
Table 101. Asia-Pacific Insulin Biosimilars Sales Quantity by Region (2025-2030) & (K Units)
Table 102. Asia-Pacific Insulin Biosimilars Consumption Value by Region (2019-2024) & (USD Million)
Table 103. Asia-Pacific Insulin Biosimilars Consumption Value by Region (2025-2030) & (USD Million)
Table 104. South America Insulin Biosimilars Sales Quantity by Type (2019-2024) & (K Units)
Table 105. South America Insulin Biosimilars Sales Quantity by Type (2025-2030) & (K Units)
Table 106. South America Insulin Biosimilars Sales Quantity by Application (2019-2024) & (K Units)
Table 107. South America Insulin Biosimilars Sales Quantity by Application (2025-2030) & (K Units)
Table 108. South America Insulin Biosimilars Sales Quantity by Country (2019-2024) & (K Units)
Table 109. South America Insulin Biosimilars Sales Quantity by Country (2025-2030) & (K Units)
Table 110. South America Insulin Biosimilars Consumption Value by Country (2019-2024) & (USD Million)
Table 111. South America Insulin Biosimilars Consumption Value by Country (2025-2030) & (USD Million)
Table 112. Middle East & Africa Insulin Biosimilars Sales Quantity by Type (2019-2024) & (K Units)
Table 113. Middle East & Africa Insulin Biosimilars Sales Quantity by Type (2025-2030) & (K Units)
Table 114. Middle East & Africa Insulin Biosimilars Sales Quantity by Application (2019-2024) & (K Units)
Table 115. Middle East & Africa Insulin Biosimilars Sales Quantity by Application (2025-2030) & (K Units)
Table 116. Middle East & Africa Insulin Biosimilars Sales Quantity by Region (2019-2024) & (K Units)
Table 117. Middle East & Africa Insulin Biosimilars Sales Quantity by Region (2025-2030) & (K Units)
Table 118. Middle East & Africa Insulin Biosimilars Consumption Value by Region (2019-2024) & (USD Million)
Table 119. Middle East & Africa Insulin Biosimilars Consumption Value by Region (2025-2030) & (USD Million)
Table 120. Insulin Biosimilars Raw Material
Table 121. Key Manufacturers of Insulin Biosimilars Raw Materials
Table 122. Insulin Biosimilars Typical Distributors
Table 123. Insulin Biosimilars Typical Customers
List of Figures
Figure 1. Insulin Biosimilars Picture
Figure 2. Global Insulin Biosimilars Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Insulin Biosimilars Consumption Value Market Share by Type in 2023
Figure 4. Rapid-Acting Biosimilars Examples
Figure 5. Long-Acting Biosimilars Examples
Figure 6. Premixed Biosimilars Examples
Figure 7. Global Insulin Biosimilars Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 8. Global Insulin Biosimilars Consumption Value Market Share by Application in 2023
Figure 9. Type I Diabetes Examples
Figure 10. Type II Diabetes Examples
Figure 11. Global Insulin Biosimilars Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 12. Global Insulin Biosimilars Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 13. Global Insulin Biosimilars Sales Quantity (2019-2030) & (K Units)
Figure 14. Global Insulin Biosimilars Average Price (2019-2030) & (USD/Unit)
Figure 15. Global Insulin Biosimilars Sales Quantity Market Share by Manufacturer in 2023
Figure 16. Global Insulin Biosimilars Consumption Value Market Share by Manufacturer in 2023
Figure 17. Producer Shipments of Insulin Biosimilars by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
Figure 18. Top 3 Insulin Biosimilars Manufacturer (Consumption Value) Market Share in 2023
Figure 19. Top 6 Insulin Biosimilars Manufacturer (Consumption Value) Market Share in 2023
Figure 20. Global Insulin Biosimilars Sales Quantity Market Share by Region (2019-2030)
Figure 21. Global Insulin Biosimilars Consumption Value Market Share by Region (2019-2030)
Figure 22. North America Insulin Biosimilars Consumption Value (2019-2030) & (USD Million)
Figure 23. Europe Insulin Biosimilars Consumption Value (2019-2030) & (USD Million)
Figure 24. Asia-Pacific Insulin Biosimilars Consumption Value (2019-2030) & (USD Million)
Figure 25. South America Insulin Biosimilars Consumption Value (2019-2030) & (USD Million)
Figure 26. Middle East & Africa Insulin Biosimilars Consumption Value (2019-2030) & (USD Million)
Figure 27. Global Insulin Biosimilars Sales Quantity Market Share by Type (2019-2030)
Figure 28. Global Insulin Biosimilars Consumption Value Market Share by Type (2019-2030)
Figure 29. Global Insulin Biosimilars Average Price by Type (2019-2030) & (USD/Unit)
Figure 30. Global Insulin Biosimilars Sales Quantity Market Share by Application (2019-2030)
Figure 31. Global Insulin Biosimilars Consumption Value Market Share by Application (2019-2030)
Figure 32. Global Insulin Biosimilars Average Price by Application (2019-2030) & (USD/Unit)
Figure 33. North America Insulin Biosimilars Sales Quantity Market Share by Type (2019-2030)
Figure 34. North America Insulin Biosimilars Sales Quantity Market Share by Application (2019-2030)
Figure 35. North America Insulin Biosimilars Sales Quantity Market Share by Country (2019-2030)
Figure 36. North America Insulin Biosimilars Consumption Value Market Share by Country (2019-2030)
Figure 37. United States Insulin Biosimilars Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 38. Canada Insulin Biosimilars Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 39. Mexico Insulin Biosimilars Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 40. Europe Insulin Biosimilars Sales Quantity Market Share by Type (2019-2030)
Figure 41. Europe Insulin Biosimilars Sales Quantity Market Share by Application (2019-2030)
Figure 42. Europe Insulin Biosimilars Sales Quantity Market Share by Country (2019-2030)
Figure 43. Europe Insulin Biosimilars Consumption Value Market Share by Country (2019-2030)
Figure 44. Germany Insulin Biosimilars Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 45. France Insulin Biosimilars Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 46. United Kingdom Insulin Biosimilars Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 47. Russia Insulin Biosimilars Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 48. Italy Insulin Biosimilars Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 49. Asia-Pacific Insulin Biosimilars Sales Quantity Market Share by Type (2019-2030)
Figure 50. Asia-Pacific Insulin Biosimilars Sales Quantity Market Share by Application (2019-2030)
Figure 51. Asia-Pacific Insulin Biosimilars Sales Quantity Market Share by Region (2019-2030)
Figure 52. Asia-Pacific Insulin Biosimilars Consumption Value Market Share by Region (2019-2030)
Figure 53. China Insulin Biosimilars Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 54. Japan Insulin Biosimilars Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 55. Korea Insulin Biosimilars Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 56. India Insulin Biosimilars Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 57. Southeast Asia Insulin Biosimilars Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 58. Australia Insulin Biosimilars Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 59. South America Insulin Biosimilars Sales Quantity Market Share by Type (2019-2030)
Figure 60. South America Insulin Biosimilars Sales Quantity Market Share by Application (2019-2030)
Figure 61. South America Insulin Biosimilars Sales Quantity Market Share by Country (2019-2030)
Figure 62. South America Insulin Biosimilars Consumption Value Market Share by Country (2019-2030)
Figure 63. Brazil Insulin Biosimilars Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 64. Argentina Insulin Biosimilars Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 65. Middle East & Africa Insulin Biosimilars Sales Quantity Market Share by Type (2019-2030)
Figure 66. Middle East & Africa Insulin Biosimilars Sales Quantity Market Share by Application (2019-2030)
Figure 67. Middle East & Africa Insulin Biosimilars Sales Quantity Market Share by Region (2019-2030)
Figure 68. Middle East & Africa Insulin Biosimilars Consumption Value Market Share by Region (2019-2030)
Figure 69. Turkey Insulin Biosimilars Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 70. Egypt Insulin Biosimilars Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 71. Saudi Arabia Insulin Biosimilars Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 72. South Africa Insulin Biosimilars Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 73. Insulin Biosimilars Market Drivers
Figure 74. Insulin Biosimilars Market Restraints
Figure 75. Insulin Biosimilars Market Trends
Figure 76. Porters Five Forces Analysis
Figure 77. Manufacturing Cost Structure Analysis of Insulin Biosimilars in 2023
Figure 78. Manufacturing Process Analysis of Insulin Biosimilars
Figure 79. Insulin Biosimilars Industrial Chain
Figure 80. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 81. Direct Channel Pros & Cons
Figure 82. Indirect Channel Pros & Cons
Figure 83. Methodology
Figure 84. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
Sanofi S.A. Boehringer Ingelheim Eli Lilly & Co. Novo Nordisk A/S Biocon Geropharm Wockhardt Gan&Lee Pharmaceuticals The United Laboratories International Tonghua Dongbao Pharmaceutical
Related Reports
26 Feb 2023
Pharma & Healthcare
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
